Bullish option flow detected in Biogen (BIIB) with 2,803 calls trading, 2x expected, and implied vol increasing over 2 points to 32.79%. Jan-26 110 calls and Jan-26 190 calls are the most active ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $190.00. The company’s shares closed yesterday at ...

Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

(Reuters) - Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs. However, the drugmaker's ...

We think Biogen's neurology, immunology ... and make sure their analysis is clear and in no way misleading or deceptive. To further protect the integrity of our editorial content, we keep a ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...

What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 bi ...